Top Medical News
Pearl Toh, 11 hours ago
Young, healthy individuals at low risk for atherosclerotic cardiovascular disease (ASCVD) events may still face a heightened lifetime risk of death from CV events if they have elevated LDL-C levels of ≥160 mg/dL, reveal the CCLS*.
12 hours ago
Mirabegron, a β3-adrenoreceptor agonist, poses no increased cardiovascular risk when used as treatment for overactive bladder syndrome, a new study has found.
16 hours ago
Intensive statin therapy in the secondary prevention of ischaemic stroke or transient ischaemic attack significantly increases the risk of premature discontinuation as compared with a moderate intensity, a study has found.
Elevated lipoprotein(a) [Lp(a)] carries an increased risk of cardiovascular (CV) events in patients with established CV disease independent of low-density lipoprotein cholesterol, according to a study. PCSK9 inhibition with evolocumab reduces Lp(a) levels, and the cardioprotective effect is pronounced in patients with higher Lp(a) levels at baseline.
Tristan Manalac, Yesterday
Amiodarone effectively controls ventricular tachycardia and ventricular fibrillation (VT/VF) regardless of left ventricular ejection fraction in atrial fibrillation (AF) patients with implantable cardioverter defibrillators (ICDs), according to a recent study.
The complexity of coronary artery disease (CAD) assessed by the SYNTAX score is an independent predictor of major adverse cardiac and cerebrovascular events (MACCE) and hard cardiovascular events (HCE) in diabetes mellitus patients with multivessel CAD, suggests a recent study.
Coronary angiography does not usually identify patients with vasospastic or microvascular angina, according to a recent study. An interventional diagnostic procedure (IDP) linked to stratified medical therapy appears to be routinely feasible and improve angina in those with no obstructive coronary artery disease (CAD).
Special Reports
30 Nov 2018
Despite risk factors for cardiovascular disease (CVD) being similar around the world, the burden of CVD is not uniform across nations. Furthermore, CVD-related death in low- to middle-income countries (LMICs) has increased by two-thirds in the last 30 years, and now account for a whopping 80% of global deaths due to CVD.
30 Nov 2018
Poor adherence to statin therapy is leaving many patients with dyslipidaemia at high risk of potentially life-threatening cardiovascular events. Statins are the current standard of care for reducing the risk of cardiovascular disease in these patients and for improving life expectancy, with possible economic benefits for healthcare systems too. However, many patients with dyslipidaemia are not achieving or maintaining treatment targets because they fail to stick to their prescribed statin therapy. An article co-authored by lipidologist Peter Lansberg, and published in Vascular Health and Risk Management, considers this issue and reviews approaches to overcome non-adherence.
28 Nov 2018
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
27 Nov 2018
Through a cardiology webcast co-hosted by Pfizer, the National Heart Association of Malaysia (NHAM), and the American College of Cardiology (ACC), Dr Ong Mei Lin, Dr Aaron D. Kugelmass and Dr Tracy Wang shared their insights into the importance of secondary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
21 Nov 2018
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

27 Sep 2018
PRALUENT – alirocumab 75 mg/mL and 150 mg/mL soln for inj - sanofi-aventis
Conference Reports
Elvira Manzano, 30 Nov 2018
In what many clinicians believed was a rare breakthrough, the prescription fish oil icosapent ethyl cut the risk of ischaemic events among statin-treated patients with high triglyceride levels and either cardiovascular disease (CVD) or diabetes in the REDUCE-IT* trial, putting fish oil on the front burner.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.
Roshini Claire Anthony, 23 Nov 2018

Individuals previously diagnosed with dilated cardiomyopathy (DCM) who are considered recovered from their condition may still need to continue treatment, with a higher rate of relapse observed among patients who discontinued versus continued therapy, according to the TRED-HF* trial findings presented at AHA 2018.

Jairia Dela Cruz, 22 Nov 2018
Rapid blood pressure (BP) elevations during the second trimester of pregnancy may pose an increased risk of delivering a low birthweight (LBW) infant, as well as contribute to impaired maternal liver, kidney and coagulation functions, according to a study presented at the 2018 American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, US.
Tristan Manalac, 22 Nov 2018
Initial treatment with endovascular therapy results in better amputation-free survival in patients with critical limb ischaemia compared with open surgical bypass, according to a study presented at the American Heart Association Scientific Session 2018 (AHA 2018), held in Chicago, Illinois.
Pearl Toh, 21 Nov 2018
New-generation drug-eluting stents (DES) are superior to early-generation stents in reducing cardiovascular (CV) events and mortality out to 10 years, but there are no significant differences between new-generation stents based on biodegradable polymer and those with permanent polymer, according to the ISAR-TEST* 4 study presented at AHA 2018.
Roshini Claire Anthony, 21 Nov 2018

Individuals hospitalized with pneumonia have an elevated risk of developing major adverse cardiovascular events (MACE), with a greater risk among those with bacterial compared with viral pneumonia, according to a recent study presented at AHA 2018.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download